Research Study Summary
New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS)
This is a 12 month open label study to evaluate the patient retention rate of Fingolimod vs. approved 1st-line disease modifying therapies in adults who are in early stages of treatment for RRMS.
Patient Inclusion Criteria:
- Patients naїve to treatment OR who have been treated with no more than one DMT; total treatment less than or equal to 5 years
- For safety, certain cardiovascular conditions and medications are excluded; this will be reviewed with the study nurse
To Learn more
Date Last Changed:
July 18, 2013
Clinical Trial Snapshot
- Both Male and Female
- 18 to 65 Years
- Overall Status
- 12 Months
- Facility Type
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.